Latest News

In early December 2025, The Estée Lauder Companies and Jo Malone London launched the Jo Malone London Scent Advisor, an AI-powered, conversational tool on JoMalone.com in the US and UK that uses Google’s Gemini and Vertex AI to recreate the brand’s in-store fragrance consultation online. This digital advisor, developed by Estée Lauder’s AI and Innovation teams, signals how the company is pairing proprietary fragrance data with AI to improve online discovery and support its broader push to...

Quest Diagnostics (DGX) just deepened its neurological testing ambitions through a new collaboration with Octave Bioscience, giving nationwide access to Octave’s multiple sclerosis disease activity blood test via Quest’s 7,000 collection sites. See our latest analysis for Quest Diagnostics. That strategic push into neurology comes as sentiment around Quest has been quietly improving, with the share price at $182.56 and a strong year to date share price return of 20.93 percent, backed by a 5...

Rivian recently held its first Autonomy & AI Day, unveiling its custom 5nm Rivian Autonomy Processor (RAP1), third-generation Autonomy Compute Module (ACM3), LiDAR-enabled Gen 3 hardware for future R2 models, an AI-driven Large Driving Model, and an Autonomy+ subscription service launching in early 2026. By shifting to in-house silicon and an AI-first software stack, Rivian is trying to turn autonomy and connected services into a long-term, higher-margin revenue engine rather than relying...

If you are wondering whether Deutsche Post is still worth considering after its strong run, or if the smart money has already moved on, you are in the right place to explore what the current price really implies. The stock has climbed 3.1% over the last week, 4.0% over the past month, and is now up 38.5% year to date and 39.8% over the last year. That naturally raises the question of whether further upside remains or whether risks are building. Much of this momentum has been supported by...

How Has Cisco Systems Stock Been Performing? Cisco Systems has quietly been rewarding patient shareholders, with the stock up 36.1% over the past year and 98.4% over the last five years, turning what many once saw as a mature tech name into a solid compounder. Even in the short term, the picture is constructive, with a 5.2% gain over the last 30 days, a modest 0.2% pullback over the past week, and the shares recently closing around $77.80. This backdrop matters because it shapes how investors...

Wondering if Commerzbank’s massive run up has already priced in the upside, or if there is still value on the table? This breakdown is for you. The stock has pulled back slightly over the last month, down 1.3%, but that comes after a huge 121.3% gain year to date and a staggering 600.6% rise over five years, which naturally raises questions about what is driving this rally. Recent headlines have focused on Commerzbank’s push to streamline its business, strengthen its capital position, and...

Recently, CSX reported its fastest train velocity since early 2021 and completed major projects such as the Howard Street Tunnel and Blue Ridge subdivision ahead of schedule, enhancing network capacity and resilience. At the same time, the company is tightening its cost base and governance, including shutting an 84-year-old corporate aviation department shortly after appointing new CEO Steve Angel, signaling a sharper focus on efficiency and capital discipline. Now we’ll examine how CSX’s...

Assessing Beyond Meat after a steep slide Beyond Meat (BYND) shares keep grinding lower, recently closing near 1 dollar, and that kind of drop naturally raises the question: is this a value opportunity or a value trap for patient investors? See our latest analysis for Beyond Meat. The latest slide to around 1.09 dollars caps a brutal stretch, with a roughly 72 percent 1 year total shareholder return loss and even steeper multiyear declines in the share price return, signaling fading momentum...

Penguin Solutions, Inc. recently introduced its SMART 64GB DDR5-6400 ECC CSODIMM modules, expanding its DDR5 SODIMM lineup for high-performance computing across industrial, edge, telecom, and networking applications, with commercial- and industrial-temperature options for harsh environments. The addition of a 64GB CSODIMM with integrated clock driver and error correction meaningfully broadens Penguin’s memory portfolio, giving system designers more flexibility to optimize density, speed, and...

Wondering if ImmunityBio at around $2.36 is a speculative trap or a misunderstood bargain? You are not alone, and that is exactly what this breakdown is here to unpack. Despite a bruising longer term record, with the share price down about 17.8% over the last year and 63.4% over three years, the stock has shown signs of life recently, gaining roughly 3.1% in the past week and 14.6% over the last month, while still sitting 8.2% lower year to date. Those moves have come as investors continue...

If you have been wondering whether Capricor Therapeutics is still a smart buy after its big run, you are not alone. This stock has quickly moved from under the radar to front and center on a lot of watchlists. The share price has dipped 3.2% over the last week, but that small pullback sits on top of a 343.3% gain in the last month and a 96.2% return over the past year, with long term holders still up 593.9% over 3 years and 524.0% over 5 years. Behind those moves, investors have been...

In the past week, InnoCare Pharma reported China NMPA approval of zurletrectinib (ICP-723) for NTRK fusion-positive solid tumors in patients aged 12 and above, alongside strong efficacy and safety data, while also showcasing extensive positive clinical results for orelabrutinib and mesutoclax at the ASH 67th Annual Meeting. This marks InnoCare’s first approved solid-tumor therapy, adding a blood–brain-barrier-penetrant TRK inhibitor to its portfolio and underscoring its push to build a broad...

If you have ever looked at Main Street Capital and wondered whether the current price really reflects its underlying value, this breakdown is for you. The stock has climbed to around $62.05, delivering about 2.2% over the last week, 4.9% in the last month, 4.7% year to date, and 19.9% over the past year, with multi year gains of 114.1% over 3 years and 190.8% over 5 years reshaping how investors see its potential. Recent headlines have focused on Main Street Capital expanding its portfolio...

Teradyne (TER) just put a bigger flag in U.S. manufacturing, with Teradyne Robotics planning a new operations hub in Wixom, Michigan, to build cobots and support customers across North America. See our latest analysis for Teradyne. The Wixom hub builds on a big year for Teradyne, where enthusiasm around AI driven semiconductor demand and robotics has helped drive a roughly 72 percent 3 month share price return and a strong multi year total shareholder return, even after the latest pullback to...

Wondering if Austal at $6.23 is still a smart buy after its big run, or if you would just be chasing momentum? Let us unpack what the current price really implies about its value. The stock has slipped slightly in the short term, down 4.4% over the last week and 7.2% over the last month, but that comes after a huge rebound with shares up 101.0% year to date and 122.5% over the past year. Much of this surge has been driven by renewed optimism around Austal's defence shipbuilding contracts and...

Recent stock performance and context Trump Media and Technology Group (DJT) has been drifting lower, with the stock down about 16% over the past month and more than 37% over the past 3 months. This has prompted fresh questions about valuation and trajectory. See our latest analysis for Trump Media & Technology Group. Zooming out, the share price has slid to about $10.65 and the sharp year to date share price return decline, alongside a steep 1 year total shareholder loss, suggests momentum is...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Kestrel Gold fair value estimate is CA$0.051 Kestrel Gold's...

Natural Grocers by Vitamin Cottage (NGVC) has wrapped up FY 2025 with fourth quarter revenue of $336.1 million and basic EPS of $0.51, alongside trailing twelve month revenue of about $1.3 billion and EPS of $2.02. Over the last few quarters the company has seen revenue move from $322.7 million in Q4 2024 to $336.1 million in Q4 2025, while quarterly EPS stepped up from $0.40 to roughly the low $0.50s as net income climbed from $9.0 million to $11.8 million. With net margin rising from 2.7%...

Kite, a Gilead Sciences (GILD) company, just released new analysis showing its CAR T therapy Yescarta delivers consistent benefits as a second line option for difficult large B cell lymphoma cases. See our latest analysis for Gilead Sciences. That stronger oncology story is quietly reshaping how investors see Gilead, with the share price at $120.4 after a softer recent patch but a robust year to date share price return of 31.04 percent, backed by a 1 year total shareholder return of 33.86...

Why Peabody Energy is Back on Watchlists Peabody Energy (BTU) has quietly turned into a strong performer over the past 3 months, with the stock up roughly 58%, even as its latest annual results still show a small net loss. See our latest analysis for Peabody Energy. Zooming out, that recent strength comes after a choppy year. Peabody’s share price is now at $29.15, with momentum clearly rebuilding following a strong 90 day share price return alongside a solid five year total shareholder...

Wondering if Eli Lilly is still worth buying after its monster run, or if the upside has already been priced in? You are not alone, and that is exactly what this article aims to unpack. The stock has climbed 1.7% over the last week, 1.0% in the past month, and is up a hefty 32.1% year to date, building on a 31.2% gain over the last year and an astonishing 531.7% over five years. A big part of this momentum has been driven by excitement around Eli Lilly's obesity and diabetes treatments,...

Wondering if Arbor Realty Trust at around $8.87 is a beaten down opportunity or a value trap? Let us unpack what the numbers are really saying about the stock. Despite a modest 0.2% gain over the last 7 days, the share price is still down 3.8% over 30 days, 35.6% year to date, and 30.6% over the past year, with only a 6.9% gain over five years. This naturally raises questions about whether the market has become too pessimistic. Recently, the stock has been in the spotlight as investors...

Wondering if ASML Holding is still worth buying after its huge run, or if the smart move now is to wait for a better entry point? The stock has slipped 2.8% over the last week but is still up 3.8% over the past month, with a hefty 34.1% gain year to date and 35.9% over the last year, reinforcing its long term growth story. Recent headlines have focused on ASML's dominant role in supplying advanced lithography tools for cutting edge chips and the impact of ongoing export restrictions to...

Bio Green Med Solution, Inc.'s (NASDAQ:BGMS) value has fallen 13% in the last week, but insiders who sold US$4.8m worth...